Geistlich Pharma focuses on customer-based product development
Geistlich has carried out pioneering work in the development of biomaterials. The company is committed to responsible product development. A particular policy of Geistlich Pharma is not to launch products immediately after receiving approval (CE label). Instead, registration is followed by a pre-sales phase. During this phase, Geistlich Pharma invests a great deal of time and money in ensuring that it only actively markets those products that have been confirmed by numerous scientific and clinical data and that are successful and reliable in application.
«Our innovations are not developed behind closed doors»
Furthermore, Geistlich Pharma pursues an innovation policy that actively includes customers in research and development. Dr. Terance Hart, Chief Science Officer at Geistlich Pharma, says: «Our innovations are not developed behind closed doors – namely in our laboratories – but in close collaboration with scientists, customers and patients. This is the only way in which we can realise our aim of accomplishing pioneering work with our developments.»
Do you have any suggestions for product innovations? Please contact us here.